RobertoOrtizMDAAHIVS

Infectious Disease • Orlando, FL

STD Medicine

BLISS HEALTHCARE SERVICES Medical Director

Join to view full profile

Dr. Ortiz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ortiz's full profile

Already have an account?

Office
3901 E Colonial Dr
Orlando, FL 32803
Phone+1 407-203-5984

Fax+1 877-325-2741

Education & Training

National University of ColombiaClass of 1989

Certifications & Licensure

FL State Medical License 2000 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Practice Solution EMR, GE Healthcare, 2014

Publications & Presentations

PubMed

169 citations
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study
Paul E. Sax, Andrew R. Zolopa, Indira Brar, Richard Elion, Roberto Ortiz
Journal of Acquired Immune Deficiency Syndromes. 2014-09-01
295 citations
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou, Evgeniy Voronin, Jan van Lunzen
AIDS. 2008-07-31
379 citations
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label ...
Bonaventura Clotet, Judith Feinberg, Jan van Lunzen, Marie Aude Khuong-Josses, Andrea Antinori
Lancet. 2014-06-28

Press Mentions

As Tragedy Hits South Florida, Severe Blood Shortage LoomsJune 25th, 2021